DOMINION Study 248.619

Description:
A cross-sectional, retrospective screening and case-control study examining the frequency of, and risk factors associated with, impulse control disorders in Parkinson’s disease patients treated with MIRAPEX® (pramipexole) and other anti-parkinson agents

Design:
A cross-sectional, retrospective screening and case-control study

Eligibility:
Parkinson patients on dopamine agonists

Sponsor:
Boehringer Ingelheim Pharmaceuticals, Inc.

Contact:
Renee Pfeiffer CRNP, 412-359-8860

---

SLV308

Description:
A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s disease

Design:
Randomized, Double blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study

Eligibility:
New onset Parkinson patients not on medication

Sponsor:
Solvay Pharmaceuticals

Contact:
Renee Pfeiffer CRNP, 412-359-8860